临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Sorafenib (BAY 43-9006) tosylate
中文名称:甲苯磺酸索拉非尼
CAS号:475207-59-1
分子式: C21H16ClF3N4O3.C7H8O3S 分子量: 637.03
产品形式: Tosylate
研发状态: Recruiting
研发用途: Pancreas Cancer
研究机构: HonorHealth Research Institute; Bayer; Genentech Inc.
研发日期: October 28 2021
研发阶段: Phase 2
Sorafenib tosylate (BAY 43-9006 tosylate,NSC-724772 tosylate) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Tivozanib (AV-951)
中文名称:替沃扎尼
CAS号:475108-18-0
分子式: C22H19ClN4O5 分子量: 454.86
产品形式: free base
研发状态: Recruiting
研发用途: Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract Malignancy
研究机构: National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)
研发日期: March 4 2022
研发阶段: Phase 1 : Phase 2
Tivozanib (AV-951, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
Monomethyl auristatin E (MMAE)
中文名称:一甲基澳瑞他汀E
CAS号:474645-27-7
分子式: C39H67N5O7 分子量: 717.98
产品形式: free base
研发状态: Not yet recruiting
研发用途: B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma
研究机构: Merck Sharp & Dohme LLC
研发日期: June 4 2024
研发阶段: Phase 1 : Phase 2
Monomethyl auristatin E (MMAE, SGD-1010) is a synthetic antineoplastic agent, which is linked to a monoclonal antibody (MAB). It is also a microtubule-disrupting agent .
Chenodeoxycholic Acid
中文名称:鹅去氧胆酸; 鹅脱氧胆酸
CAS号:474-25-9
分子式: C24H40O4 分子量: 392.57
产品形式: free base
研发状态: Completed
研发用途: Chronic Diarrhea; Irritable Bowel Syndrome With Diarrhea; Bile Acid Malabsorption; Bile Acid Diarrhea; Bile Acid Malabsorption Syndrome Type II; Functional Diarrhea
研究机构: Michael Camilleri MD; NGM Biopharmaceuticals Inc; Mayo Clinic
研发日期: December 1 2021
研发阶段: Phase 2
Chenodeoxycholic Acid (Chenodiol, Chenodesoxycholic acid, Chenocholic acid,CDCA) is a naturally occurring human bile acid, and inhibits production of cholesterol in the liver and absorption in the intestines. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
Lersivirine (UK-453061)
中文名称:3-氰基-5-[[3,5-二乙基-1-(2-羟基乙基)-1H-吡唑-4-基]氧基]苯腈
CAS号:473921-12-9
分子式: C17H18N4O2 分子量: 310.35
产品形式: Free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Pfizer; ViiV Healthcare
研发日期: Nov-10
研发阶段: Phase 1
Lersivirine (UK-453061) is a potent and selective inhibitor of nonnucleoside reverse transcriptase (NNRTI) with IC50 of 0.119 μM.
Astaxanthin
中文名称:虾青素
CAS号:472-61-7
分子式: C40H52O4 分子量: 596.84
产品形式: free base
研发状态: Terminated
研发用途: Osteoarthritis Knee; Osteoarthritis Knees Both; Joint Inflammation
研究机构: Prisma Health-Midlands
研发日期: September 2 2022
研发阶段: Phase 2 : Phase 3
Astaxanthin (β-Carotene-4,4'-dione, Trans-Astaxanthin), a xanthophyll carotenoid, is a nutrient with unique cell membrane actions and diverse clinical benefits with excellent safety and tolerability. Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is a modulator of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
